GALECTIN THERAPEUTICS INC - COM NEW (GALT)

Q3 2018 13F Holders as of 30 Sep 2018

Type / Class
Equity / COM NEW
Total 13F shares
6,014,860
Share change
+440,855
Total reported value
$36,148,300
Put/Call ratio
151%
Price per share
$6.01
Number of holders
58
Value change
+$2,413,240
Number of buys
32
Number of sells
31

Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q3 2018

As of 30 Sep 2018, GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by 58 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 6,014,860 shares. The largest 10 holders included Vanguard Group Inc, D.A. DAVIDSON & CO., BlackRock Inc., Advisor Group, Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, Invesco Ltd., FIRST FOUNDATION ADVISORS, Benchmark Capital Advisors, GEODE CAPITAL MANAGEMENT, LLC, and BANK OF MONTREAL /CAN/. This page lists 58 institutional shareholders reporting positions in this security for the Q3 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.